What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants will receive one s.c. injection of SSGJ-613 on Day 1、W4、W8、W12”In the company’s words, NCT07708181 on ClinicalTrials.gov
- Tested for
- Gout Arthritis
- Main trialPhase 2
- “The purpose of this study is to determine the efficacy and safety of recombinant anti-interleukin-1β humanized monoclonal antibody injection in Chinese gout participants Initiating Urate-Lowering Treatment”In the company’s words, NCT07708181 on ClinicalTrials.gov
Other drugs for Gout Arthritis
- DapansutrileOlatec Therapeutics, Inc. · Phase 2/3
- EtoricoxibLaboratorios Silanes S.A. de C.V. · Phase 3
- AR882Arthrosi Therapeutics · Phase 2
Coming up1
- 11 Aug 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 11 Aug 2027 | A Study of SSGJ-613 in Gout Participants Initiating Urate-Lowering Treatment | |
| Phase 3Unknown | Dec 2024 | A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout | |
| Phase 2Unknown | Oct 2024 | A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment. | |
| Phase 1/2Unknown | Sep 2023 | A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout | |
| Phase 1Unknown | 30 Apr 2022 | Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection | |
| Phase 1Unknown | 10 Mar 2024 | The MAD Study of SSGJ-613 in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026